Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Hoffmann-La Roche
Endeavor Biomedicines, Inc.
Emory University
University of Alabama at Birmingham
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Fudan University
Nationwide Children's Hospital
Telix Pharmaceuticals (Innovations) Pty Limited
Instituto do Cancer do Estado de São Paulo
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Pfizer
National Cancer Institute (NCI)
Actuate Therapeutics Inc.
National Cancer Institute (NCI)
Fundació Sant Joan de Déu
University of Virginia
Memorial Sloan Kettering Cancer Center
UNICANCER
Eastern Cooperative Oncology Group
Cambridge University Hospitals NHS Foundation Trust
Memorial Sloan Kettering Cancer Center
Northwestern University
Sarcoma Alliance for Research through Collaboration
Samsung Medical Center
University of Michigan Rogel Cancer Center
Dana-Farber Cancer Institute
Memorial Sloan Kettering Cancer Center
NYU Langone Health
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
GE Healthcare
Children's Oncology Group
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University Hospital Muenster
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
European Organisation for Research and Treatment of Cancer - EORTC